Recent Updates
Recently added Catalysts
NGNE Positive Sentiment

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Key Takeaway: Neurogene Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The management will engage in a fireside chat and hold investor meetings on September 15 at 1:00 p.m. ET. This event underscores Neurogene's commitment to advancing genetic therapies for rare neurological diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurogene is actively engaging with investors.
  • Participation in a reputable conference highlights company visibility.
  • Focus on life-changing genetic medicines for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~28 mo
Minimal dilution risk
Lead asset
NL-201
Phase 1 · Solid Tumor

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, September 15 at 1:00 p.m. ET A live webcast of the fireside chat will be accessible from

Frequently Asked Questions

When will Neurogene participate in the conference?

Neurogene will participate on September 15 at 1:00 p.m. ET.

What format will Neurogene's participation take?

Neurogene management will engage in a fireside chat and investor meetings.

What is the focus of Neurogene's work?

Neurogene focuses on genetic medicines for rare neurological diseases.

Last updated: Sep 8, 2026